Rest AP-Haloperidol

From Psychiatrienet
Revision as of 16:25, 14 August 2009 by Verena (talk | contribs) (Created page with '{{Drugswitch | from = Rest AP | to = Haloperidol | stop = {{StopStand}} | start = {{StartStand}} | info = {{caveQT}} | view = Switchstandaardup en down.jpg }}')
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search
Rest anti-psychotics

Chlorprothixene
Flupentixol
Loxapine
Pericyazine
Perphenazine
Trifluoperazine
Ziprasidone
Zuclopenthixol

Haloperidol
Type Antipsychotic
Group Butyrophenones
links
ATC-code N05AD01
Medscape Haloperidol
PubChem 3559
PubMed Haloperidol
Drugs.com haloperidol
Kompas (Dutch) Haloperidol
Wikipedia Haloperidol

Switch medication from Rest AP to Haloperidol.[5] [6]

Nietinrijdenbord.png Stop Rest AP
  • Day 1-4: approx. 75% of initial dose
  • Day 5-8: approx. 50% of initial dose
  • Day 9-12: approx. 25% of initial dose
  • Day 13: stop
Eenrichtingbord.png Start Haloperidol
  • Day 1-4: approx. 25% of target dose
  • Day 5-8: approx. 50% of target dose
  • Day 9-12: approx. 75% of target dose
  • Day 13: target dose
Infobord.png More information
  • During this switch you could monitor ECG, especially in patients prone to QT-conduction problems.
  • There is a possibility of QT interval prolongation.[7]
    Switchstandaardup en down.jpg
Nietinrijdenbord.png — Rest AP
Eenrichtingbord.png — Haloperidol


  1. WHO Collaborating Centre for Drug Statistics Methodology ATC=N05AD01
  2. 2.0 2.1 2.2 KNMP; Informatorium Medicamentorum 2023; Monografie "haloperidol" (Dutch)
  3. 3.0 3.1 The Lundbeck Institute; Psychotropics; Terminal Plasma Half-lives
  4. 4.0 4.1 Farmacotherapeutisch Kompas; Inleidende Tekst Antipsychotica (dutch)
  5. Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  6. Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
  7. Stöllberger C, Huber JO, Finsterer J, Antipsychotic drugs and QT prolongation. Int Clin Psychopharmacol. 2005 Sep;20(5):243-51.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.